The overall objective of these studies was to determine whether IgG antibody to Pseudomonas aeruginosa would modify the acute lung and pleural injury that developed over 24 h after the instillation of 1010 live P. aeruginosa into the distal airspaces of one lung in unanesthetized sheep. Using a quantitative experimental model to measure protein permeability across the alveolar epithelial, lung endothelial, and pleural mesothelial barriers, the effect of IgG antibody to P. aeruginosa was examined under four different experimental conditions. First, the effect of IgG antibody to P. aeruginosa in the circulation was examined by instilling 1010 live P. aeruginosa in 5% ovine albumin in sheep that had been vaccinated. Under these conditions, the presence of circulating IgG antibody to P. aeruginosa reduced lung endothelial injury but did not modify the lung epithelial or pleural injury caused by intraalveolar P. aeruginosa. Therefore, the second experimental protocol determined the effect of instilling immune serum from a sheep that had been vaccinated so that IgG antibody to P. aeruginosa was present in both the circulation and in the airspaces along with instillation of live bacteria. Under these conditions, injury to the lung endothelium, alveolar epithelium, and pleural space was completely prevented. Therefore, the third protocol examined the protective effect of instillation of IgG antibody to P. aeruginosa in the airspaces concurrent with the live bacteria. Interestingly, intraalveolar IgG antibody to P. aeruginosa prevented all evidence of lung epithelial and pleural injury, and this effect was associated with a marked decrease in the number of viable bacteria in the lung after 24 h. Therefore, the fourth protocol examined the prophylactic effect of instillation of the specific IgG antibody to P. aeruginosa 24 h before instillation of the bacteria. With this prophylactic regimen, epithelial, endothelial, and pleural injury were prevented, and there was a significant decrease in the number of bacteria recovered from the lung. (3) (4) (5) . These studies have also suggested that the most protective antibodies against P. aeruginosa are opsonic rather than bactericidal, thus providing a rationale for P. aeruginosa immunization strategies that emphasize augmentation of humoral rather than cellmediated immunity (3). In contrast to older vaccines, which contained the whole endotoxin antigen, a Pseudomonas vaccine containing a high molecular weight, immunogenic 0-specific polysaccharide antigen, but lacking the toxic lipid A component, has been shown to be well tolerated and immunogenic in normal human volunteers (6). This vaccine also has been shown to achieve a plasma level of IgG antibody to P. aeruginosa comparable to the levels measured in patients who survived P. aeruginosa sepsis (7, 8) . Also, immunization with P. aeruginosa 0-specific polysaccharide antigen has improved survival after a homologous bacterial challenge in both burned and granulocytopenic mice and in a model of pneumonia in guinea pigs (9, 10) .
Introduction
The overall objective of these studies was to determine whether IgG antibody to Pseudomonas aeruginosa would modify the acute lung and pleural injury that developed over 24 h after the instillation of 1010 live P. aeruginosa into the distal airspaces of one lung in unanesthetized sheep. Using a quantitative experimental model to measure protein permeability across the alveolar epithelial, lung endothelial, and pleural mesothelial barriers, the effect of IgG antibody to P. aeruginosa was examined under four different experimental conditions. First, the effect of IgG antibody to P. aeruginosa in the circulation was examined by instilling 1010 live P. aeruginosa in 5% ovine albumin in sheep that had been vaccinated. Under these conditions, the presence of circulating IgG antibody to P. aeruginosa reduced lung endothelial injury but did not modify the lung epithelial or pleural injury caused by intraalveolar P. aeruginosa. Therefore, the second experimental protocol determined the effect of instilling immune serum from a sheep that had been vaccinated so that IgG antibody to P. aeruginosa was present in both the circulation and in the airspaces along with instillation of live bacteria. Under these conditions, injury to the lung endothelium, alveolar epithelium, and pleural space was completely prevented. Therefore, the third protocol examined the protective effect of instillation of IgG antibody to P. aeruginosa in the airspaces concurrent with the live bacteria. Interestingly, intraalveolar IgG antibody to P. aeruginosa prevented all evidence of lung epithelial and pleural injury, and this effect was associated with a marked decrease in the number of viable bacteria in the lung after 24 h. Therefore, the fourth protocol examined the prophylactic effect of instillation of the specific IgG antibody to P. aeruginosa 24 h before instillation of the bacteria. With this prophylactic regimen, epithelial, endothelial, and pleural injury were prevented, and there was a significant decrease in the number of bacteria recovered from the lung. Thus, delivery of IgG antibody to P. aeruginosa the distal airspaces of the lung alone may provide a novel therapeutic approach to preventing acute pulmonary infection caused by P. aeruginosa. (J. Clin. Invest. 1993 . 92:1221-1228.) Key words: Pseudomonas aeruginosa * pneumonia -alveolar epithelium * pleural empyema * immunization * host immunity * lung Pseudomonas aeruginosa is the most frequently isolated pathogen from patients with nosocomial pneumonia (1) . Despite the use ofpotent antibiotics, the mortality rate ofP. aeruginosa pneumonia remains between 50 and 80% (2) , establishing the need for new treatment modalities or improved prophylactic measures. Earlier studies have established that serotype-specific humoral immunity results in a significant augmented host defense against blood-borne P. aeruginosa (3) (4) (5) . These studies have also suggested that the most protective antibodies against P. aeruginosa are opsonic rather than bactericidal, thus providing a rationale for P. aeruginosa immunization strategies that emphasize augmentation of humoral rather than cellmediated immunity (3) . In contrast to older vaccines, which contained the whole endotoxin antigen, a Pseudomonas vaccine containing a high molecular weight, immunogenic 0-specific polysaccharide antigen, but lacking the toxic lipid A component, has been shown to be well tolerated and immunogenic in normal human volunteers (6) . This vaccine also has been shown to achieve a plasma level of IgG antibody to P. aeruginosa comparable to the levels measured in patients who survived P. aeruginosa sepsis (7, 8) . Also, immunization with P. aeruginosa 0-specific polysaccharide antigen has improved survival after a homologous bacterial challenge in both burned and granulocytopenic mice and in a model of pneumonia in guinea pigs (9, 10) .
However, the magnitude of protection provided by active immunization against P. aeruginosa in modulating the bacterial injury to the different barriers of the lung has not specifically been studied. We have previously developed an experimental animal model that quantifies liquid, protein, and cellular movement across the alveolar epithelial, lung endothelial, and visceral pleural barriers of the intact lung in normal and pathological conditions ( 1 1-13). We have also reported that P. aeruginosa pneumonia causes injury to the lung epithelial barrier in unanesthetized sheep studied over 24 h ( 13).
Therefore, the first objective of these studies was to determine the value of IgG antibody to P. aeruginosa, elicited by active immunization against P. aeruginosa (Fisher type 1), in modulating the lung and pleural injury caused by the instillation of homologous 1010 live P. aeruginosa bacteria into the airspaces of awake sheep. In these initial studies, circulating IgG antibody to P. aeruginosa alone did not prevent the bacterial injury to the alveolar epithelium nor the formation of protein-rich pleural effusions. Therefore, another group of experiments examined the effect of instilling autologous immune serum from vaccinated sheep into the airspaces concurrent with the instillation of live P. aeruginosa bacteria to test whether the presence of IgG antibody to P. aeruginosa in both the circulation and the airspaces of the lung was beneficial. These studies demonstrated complete protection against all in-jury from P. aeruginosa. Therefore, we tested the hypothesis that IgG antibody to P. aeruginosa in the airspaces alone could provide significant protection against P. aeruginosa-induced acute lung and pleural injury. In one group of sheep, IgG antibody to P. aeruginosa was instilled into the airspaces in nonvaccinated sheep concurrent with instillation of P. aeruginosa and, in the final group of sheep, the IgG antibody was instilled 24 h before the instillation of the bacteria.
Methods

Surgical preparation and ventilation
A total of42 female and wethered yearling sheep (31±4 kg; mean±SD) were studied. All of the sheep were initially given pentothal (30 mg/ kg), intubated, and ventilated with a constant-volume pump (Harvard Apparatus, Millis, MA) at a tidal volume of 400-500 ml ( 13-15 ml/ kg) with a peak inspiratory pressure of 15-20 cm H20 and a positive end-expiratory pressure of 5 cm H20. The respiratory rate was adjusted to achieve an arterial partial pressure ofcarbon dioxide between 30 and 40 mmHg. Anesthesia was maintained with 1.0-1.5% halothane mixed with supplemental oxygen (40-60%). Catheters were inserted into the carotid artery and the external jugular vein. Then, the sheep were placed in a prone position with their head and thorax elevated at a 50 angle to maintain the lower lung lobes in a slightly dependent position. The preparatory surgery required -45-60 min. All experiments were done in compliance with the University of California San Francisco Animal Care Committee rules and all protocols were approved.
Preparation ofinstillate
When autologous serum was used as the instillate, the sheep had 250 ml of blood drawn the day before the experiment to prepare autologous serum. The blood was withdrawn using sterile technique, clotted, and centrifuged to obtain serum. The serum was refrigerated overnight and, the next morning, the solution was filtered through a 0.2-,gm filter (Nalge Co., Rochester, NY), and 10 mg ofanhydrous Evan's blue and 15 ttCi of '251-labeled HSA (Merck-Frosst, Quebec, Canada) were added to the sheep's serum, as we have done in earlier studies ( 1 1-13). Evan's blue was used to be certain that the instilled serum was confined to the instilled lower lobe. A sample ofthe labeled serum was saved for radioactivity counts and wet/dry weight ratio measurements so that the dry weight of the serum could be subtracted from the final lung water calculation.
In experiments in which 5% ovine albumin was instilled, a 5.0 g/ 100 ml solution in Ringer's lactate that was isosmolar with plasma was prepared; the solution was filtered through a 0. were then added. In the final group ofexperiments, the IgG antibody to P. aeruginosa in lactated Ringer's (same concentration as in sheep plasma) was instilled 24 h before the instillation of the 5% ovine albumin solution containing the bacteria.
General protocol
For all experimental studies, the following general protocol was used.
After surgery, a 1-h baseline period was required before alveolar liquid instillation. Using a fiberoptic bronchoscope (Machida America Inc., Norwood, NJ), 3 ml/kg ofthe instillate was instilled (see specific protocols) into the right lower lobe. By using a three-way t-piece adapter on the endotracheal tube, ventilation was maintained during the bronchoscopy. At the end of instillation, 10 MCi of 1"'I-labeled human albumin were injected intravenously. This vascular tracer was used to calculate the flux ofplasma protein entering the airspaces ofthe lungs (see below). Then, the sheep were allowed to recover from anesthesia and were extubated when they were awake and spontaneously breathing. They were placed in a metabolic cart for 24 h with free access to food and water.
24 h later they were given intravenous ketamine (10 mg/kg) and exsanguinated. The lungs were removed through a sternotomy and 1-2 ml of alveolar liquid was obtained by passing a 3-mm-diameter catheter into the distal airways ( I 1-13 ) . Aftercentrifugation, the radioactivity of the alveolar liquid sample was measured. In an earlier study, we reported that the concentration ofthe protein tracers in the liquid sampled by a 3-mm catheter wedged into the distal airways was the same as in a directly obtained alveolar micropuncture sample ( 14) . Extravascular lung water was measured on both lungs separately (see Measurements).
Specific protocols
Group JA: Control sheep instilled with a protein solution alone (n = 13). After the baseline period, autologous serum (n = 4) or 5% ovine albumin solution (n = 9) was instilled into the right lower lobe. Then, the sheep were studied for 24 h. After this time interval, the sheep were exsanguinated and processed as described above (see General protocol). The data for the control sheep instilled with either autologous serum (n = 4) or 5% ovine albumin (n = 9) have been combined because there was no significant difference between the results from the two group subsets (data not shown).
Group IB: Control sheep instilled with P. aeruginosa bacteria (positive controls) (n = 5). 10 ml oflive P. aeruginosa ( I09 CFU/ml) were mixed with a 5% ovine albumin solution in Ringer's lactate and instilled into the right lower lobe. Then, the sheep were studied and processed as described above.
Group 2: Instillation ofP. aeruginosa bacteria in sheep with circulating IgG antibody to P. aeruginosa (n = 7). Preimmune serum was obtained and the sheep were vaccinated intramuscularly with 100 ,ug of the P. aeruginosa immunotype I high molecular weight polysaccharide once a week for 3 wk (6). After 3 wk, an increase in the IgG antibody level to P. aeruginosa was measured in the circulating serum. Then, 10 ml of live P. aeruginosa (109 CFU/ml) was mixed with a 5% ovine albumin solution in Ringer's lactate and instilled into the right lower lobe. The sheep were then studied and processed as described above. To assess whether IgG antibody to P. aeruginosa entered the airspaces of the lung, both lungs of two additional vaccinated sheep were lavaged with 1,000 ml of isotonic saline using 1 50-ml aliquots. We recovered and pooled 750-800 ml from each lung.
Group 3: Instillation of live P. aeruginosa bacteria in sheep with circulating and alveolar IgG antibody to P. aeruginosa (n = 9). Preimmune serum was obtained and the sheep were vaccinated intramuscularly with 100 ug of the P. aeruginosa immunotype I high molecular weight polysaccharide once a week for 3 wk. After 3 wk, IgG antibody to P. aeruginosa level was measured in the circulating serum. Then, 10 ml of live P. aeruginosa (109 CFU/ml) was mixed with autologous hyperimmune serum and instilled into the right lower lobe. The sheep were studied and processed as described above.
Group 4: Instillation ofP. aeruginosa bacteria in sheep with alveolar IgG antibody to P. aeruginosa (n = 4). IgG was isolated from serum obtained from an immunized donor sheep (see preparation of instillate). Then, 1% IgG antibody to P. aeruginosa was mixed with ovine albumin and Ringer's lactate to prepare a 5% protein solution and instilled with 10 ml of live P. aeruginosa ( I09 CFU/ml) into the right lower lobe of nonimmune sheep. The sheep were then studied and processed as described above.
Group 5: Instillation ofP. aeruginosa bacteria in sheep that were pretreated with alveolar IgG antibody to P. aeruginosa (n = 4). IgG was isolated from serum obtained from an immunized donor sheep (see Preparation of instillate). Then 4 ml/kg of 1% IgG antibody was instilled into the right lower lobe of nonimmune sheep. The sheep were extubated after they were awake. 24 h later, 10 ml of I09 CFU P. aeruginosa was added to a 5% ovine albumin instillate and the instillate was placed in the same location in the right lower lobe as the IgG had been placed. The animal was again extubated after recovery and then studied and processed as in the other protocols.
Measurements ofhemodynamics
Systemic arterial and airway pressures were measured continuously during the surgical preparation and the instillation of P. aeruginosa into the airspaces of the lung.
Lung endothelial and alveolar epithelial barrier protein permeability Two different methods were used to measure the bidirectional flux of albumin across the lung epithelial barrier, as we have used before (11) (12) (13) (14) . The first method required measurement of the residual '25I-albumin (the alveolar protein tracer) in the lung as well the accumulation of 1251-albumin in the plasma. The second method required the measurement of '31I-albumin (the vascular protein tracer) in the lungs and the airspace of the lung.
The total quantity of '251-albumin (the alveolar protein tracer) instilled into the lung was determined by measuring duplicate samples of the instilled solution for total counts (cpm/g) and then multiplying this data by the total volume instilled into the lung. To calculate the residual 1251I-albumin in the lung after 24 h, the average radioactivity counts of two 0.5-g samples obtained from the lung homogenate (see below) were multiplied by the total volume of the lung homogenate. The '25I-albumin in the lung homogenate data was added to the recovered counts in the final aspirate of alveolar fluid to calculate the amount of instilled '25I-albumin that remained in the lung after 24 h. The 1251-albumin in the circulating plasma was measured from a sample of plasma obtained at the end ofthe experiment. The plasma fraction was accounted for by multiplying the counts per milliliter times the plasma volume (body weight X 0.07 [1 - 
The second method required measurement of the vascular protein tracer, '31I-albumin, in the final alveolar sample. The 31I-albumin counts in the plasma over the course ofthe experiment were averaged, and the '3'1-albumin counts in the final airspace samples were expressed as a ratio to the plasma counts. Alveolar liquid was obtained by passing a 3-mm-diameter catheter into the distal airways ofthe instilled lung and aspirating 1-2 ml of alveolar fluid. The sample was centrifuged and the radioactivity (counts per milliliter) of the supernatant were measured. This ratio provided a good index ofequilibration ofthe vascular protein tracer into the alveolar compartment, as we and other investigators have shown in other experimental studies of lung epithelial permeability ( 12, 13, 15) . Also, the accumulation ofthe vascular protein tracer in the extravascular space of the lungs was used as an index ofendothelial permeability. The accumulation of the vascular protein tracer, '3'I-albumin, is expressed as milliliters and is calculated by determining the total extravascular counts of 131I-albumin in the lung divided by the average counts in the plasma over 24 h, as we have done before ( 13 ) .
Trichloracetic precipitation established that protein tracers in the instillate, alveolar liquid, and plasma were always > 98% protein bound.
Measurement ofexcess water in the lung and pleural space
To determine the excess water in the lung and the pleural space after 24 h, we used the following methods. For determination of the excess extravascular water in the instilled versus the contralateral control lung, standard methods were used, as in our earlier studies ( 1 1-13, 16 ).
Before exsanguination, a 40-ml blood sample was obtained to measure the hemoglobin concentration and the water/dry weight ratio ofblood for the lung water calculation. Each lung was separately homogenized and the extravascular lung water was determined by calculating the water/dry weight ratio. Briefly, the volume of the excess extravascular lung water (ELW)' ofthe instilled experimental lung was calculated as the difference between the water/dry weight ratios ofthe experimental and contralateral lungs multiplied by the dry weight ofthe experimental lung. The dry weight ofthe instilled experimental lung was corrected for the dry weight of the instilled protein remaining in the lung at the end of the experiment. To determine the mass of protein remaining, the dry weight of the instillate was multiplied by the fraction of '25I-albumin remaining in the lung. This value was then subtracted from the total dry weight of the experimental lung.
The equation is ELW (ml) = [W./(De -P) -Wc/DcI(Dc -P) in which Wand D are extravascular lung water and blood-free dry weight of the experimental lung, e, and the control lung, c, P is the blood-free dry weight ofthe instilled 5% ovine albumin solution multiplied by the fraction of '25I-albumin remaining in the lung after 24 h. Our previous study demonstrated the importance of the pleural space as a pathway for draining excess fluid from the lung ( 17) . Therefore in these studies, the final pleural water volume measured in the pleural space after 24 h has been added to the ELW to provide a more accurate indication of the total lung and pleural fluid balance.
Measurement ofIgG antibody to P. aeruginosa Plasma antibody levels to the immunotype 1 strain of P. aeruginosa were quantified by a radioactive antigen binding assay using intrinsically 14C-labeled high molecular weight polysaccharide prepared as previously described (6, 18) .
Growth and culturing oflive P. aeruginosa A clinical isolate of P. aeruginosa, Fisher immunotype 1 was used for all these studies. These bacteria were maintained in peptone broth containing 25% glycerol at -70'C. Before an experiment, the broth was thawed and the organisms were transferred to blood agar plates (5% sheep erythrocytes) for 24 h. Overnight cultures were transferred to fresh medium, tryptone soy broth, for another 24 h. On the day of experiment, the bacteria were sedimented in a clinical centrifuge and resuspended to a final concentration of 109 CFU/ml in sterile PBS. Then, the Pseudomonas solution ( 10 ml of 109 CFUI/ml) was centrifuged at 1,500 g for 15 min. The pellet of bacteria was washed twice with PBS, and was resuspended in 10 ml of the same solution.
Before intraalveolar instillation, a sample was taken for quantitative culture. Samples of blood, pleural fluid, alveolar fluid, and lung homogenate were obtained aseptically for culture at the end of the experiments. The concentration of bacteria was then quantified by plating successive 10-fold dilutions of the bacterial suspension onto sheep blood agar plates and by scoring visible colonies after 24 h incubation at 37°C. All colonies were also subcultured to identify P. aeruginosa organisms. Routine biochemical screening and antibiotic sensitivity testing were done to ensure the P. aeruginosa strain has not changed between experiments.
Statistics
The data are summarized as mean and standard deviation. One-way analysis of variance followed by Scheffe Ftest was used to compare the different animal groups. We regarded as statistically significant those differences with a P value of < 0.05 (19) .
Results
Specific immunity. There was no detectable level of IgG antibody to P. aeruginosa in either the peripheral blood or in the alveolar fluid samples of the control sheep (group 1) that re-ceived a protein solution alone or live P. aeruginosa (Table I) . In contrast, after active immunization with immunotype I Pseudomonas polysaccharide antigen (group 2), the mean plasma concentration ofIgG antibody to P. aeruginosa was 3.7 ,Ag/ml, with no antibody detected in these vaccinated group 2 sheep in the final alveolar fluid sample (Table I ). In the group 3 sheep that were both immunized and instilled with immune serum, the concentration of IgG antibody was similar in the circulating plasma and the instilled immune serum (Table I) . Interestingly, the concentration of IgG antibody to P. aeruginosa measured 24 h later in the final alveolar fluid samples of both groups 3, 4, and 5 were two to four times greater than those measured in the instillate (Table I) , probably reflecting net alveolar liquid clearance, as in our earlier studies ( 12, 13 The sheep with circulating IgG antibody to P. aeruginosa alone (group 2) had a similar increase in excess water in the lung and pleural space after 24 h. In contrast, concurrent instillation of IgG antibody to P. aeruginosa into the airspaces (groups 3 and 4) or pretreatment with IgG antibody (group 5) prevented any significant increase in excess water in the lung and pleural space.
nonimmune sheep (Table III) . The group 4 sheep still had a slight increase in the influx of plasma into the interstitium of the lung, but this effect was not present in the group 5 sheep that were treated with IgG 24 h before the instillation of the bacteria (Table III) .
Lung and pleural fluid balance. The quantity of excess water remaining in the instilled lung and the pleural space after 24 h after instillation of P. aeruginosa (group IB) was more than double the volume recovered in control studies (group 1A) (Fig. 1 ) . The sheep with circulating antibody alone (group 2) had a similar increase in excess water in the lung and pleural space after 24 h (Fig. 1) . However, the presence of IgG antibody to P. aeruginosa in the circulation and the airspaces (group 3) was not associated with any increase in excess water (Fig. 1 ) . IgG antibody to P. aeruginosa instilled in the airspaces with the bacteria (group 4) was associated with a 60% mean reduction in excess water and pretreatment with specific IgG 24 h before bacterial instillation (group 5) was not associated with any increase in the excess water (Fig. 1) .
Protein permeability across the pleura. Instillation of P. aeruginosa into the airspaces of the lung of nonimmune sheep (group iB) was associated with a significant movement (10-fold increase) of both alveolar protein tracer and the vascular protein tracer (2-fold increase) into the pleural space adjacent to the instilled lung (Table IV) . The presence of circulating IgG antibody to P. aeruginosa (group 2) did not prevent this increased influx of the alveolar and vascular protein tracers into the pleural space. However, when immune serum was instilled in the vaccinated sheep (group 3) or IgG antibody to P. aeruginosa was instilled with P. aeruginosa into the airspaces of nonimmune sheep (group 4), or 24 h before bacterial instillation (group 5), the influx of the alveolar protein tracer into the pleural space was completely prevented (Table IV) .
The protein concentration of the pleural fluid adjacent to the instilled lung was significantly increased in the nonimmune sheep instilled with P. aeruginosa (group 1B) and in the sheep with only circulating antibody (group 2) (Table IV ). In contrast, in groups 3, 4, and 5, the protein concentration in the pleural fluids did not increase (Table IV) .
Also, the volume of the pleural fluid adjacent to the instilled lung was 5.4±3.0 ml in the control sheep instilled with a protein solution alone (group IA) ( Table IV) . The mean volume of the pleural fluid doubled in the nonimmune sheep instilled with P. aeruginosa (group IB) and in the vaccinated sheep with circulating IgG antibody to P. aeruginosa (group 2); however, the volume of pleural fluid was normal in groups 3, 4, and 5 (Table IV) .
Bacteriological cultures. The number of colony-forming units of bacteria instilled into the airspaces of the lung was similar in all the P. aeruginosa experiments (Table V) . The final number ofbacteria measured in the lung homogenate was similar in the nonimmune sheep that received P. aeruginosa (group IB) and those sheep with only circulating IgG antibody to P. aeruginosa (group 2) (Table V) . In contrast, when IgG antibody to P. aeruginosa was present in the instilled solution in either the immune, vaccinated sheep (group 3) or in the nonvaccinated sheep (group 4), there was at least a 10-fold decrease in the number ofmicroorganisms recovered after 24 h (Table V) . In the pretreated sheep (group 5), there was a twofold reduction in the number oforganisms recovered after 24 h. The instillation of the IgG antibody to P. aeruginosa also prevented the dissemination ofP. aeruginosa to the pleural space, as confirmed by the negative pleural fluid cultures obtained after 24 h in all but 1 of 13 sheep (groups 3, 4, and 5) ( Table  V) . In contrast, when P. aeruginosa was instilled without specific antibody in the nonimmune sheep (group IB) and in the sheep with only circulating antibody (group 2), 50% of the pleural fluid cultures were positive for P. aeruginosa at the end of the experiment. Blood cultures were sterile in all the experiments.
Discussion
The first objective of these studies was to determine the effect of circulating IgG antibody to P. aeruginosa in modifying the homologous bacterial injury to the different barriers of the lung. The vaccinated sheep (group 2) developed levels ofcirculating specific antibody that have been shown to be protective (6) (Table I ). However, no detectable quantity of IgG antibody to P. aeruginosa was found in the final alveolar sample (Table I ). The lack of bacterial killing in the final alveolar sample from these sheep ( Table V ) also indicates that very little ofthe IgG antibody to P. aeruginosa entered the airspaces of the lung. Therefore, the inability of significant quantities of IgG antibody to P. aeruginosa to penetrate into the airspaces probably accounts for the lack of protection in the group 2 sheep against injury to the epithelial and pleural barriers. There are three possible explanations for the finding that IgG antibody to P. aeruginosa in the circulation did not enter the airspaces of the vaccinated sheep in significant quantity.
Although a small quantity of 3"I-albumin entered the airspaces from the plasma, the epithelial leak produced by the airspace bacteria might have been inadequate to allow the entry of Our results differ from those of two previous studies conducted in small animals in which active or passive immunization against P. aeruginosa increased the pulmonary clearance of these bacteria (22, 23) . This difference may be explained first by the fact that, in sheep, the intraalveolar administration of P. aeruginosa did not cause a rapid fatal disease as reported for smaller animals (22, 23) . Therefore, our animal model may be more representative of critically ill patients who develop a nosocomial pneumonia since the airways of these patients are progressively colonized with Pseudomonas bacteria before the pneumonia becomes clinically apparent (24) . Secondly, since the lung injury was much more severe in the smaller animal studies, the influx of plasma proteins into the airspaces of the lung should have been greater, explaining why there was an increased quantity of IgG antibody to P. aeruginosa at the end of the studies in the airspaces of both immunized mice (23) and guinea pigs (22) compared with the level of IgG antibody to P. aeruginosa that we measured in the airspaces ofourimmunized sheep. However, the IgG antibody to P. aeruginosa was not increased in the bronchoalveolar lavage carried out before the instillation of bacteria in the immunized mice, indicating that the active immunization itself did not increase the IgG in the airspaces ofthe lung (23) . In addition, in these immunized mice, the number of bacteria in the lung over 6 h multiplied significantly, suggesting that the transfer of the IgG from the vascular space to the airspaces of the lung after the intraalveolar P. aeruginosa challenge was not sufficient to enhance bacterial killing (23) . Finally, in the previously cited studies, the most important effect of active immunization against P. aeruginosa bacteria was not a decrease in the lung damage caused by these bacteria, but a reduction in the overall mortality. This improved survival rate reported in small immunized animals seems to have been primarily related to the fact that circulating IgG antibody to P. aeruginosa prevented death from sepsis by improving clearance of P. aeruginosa from the bloodstream.
Although active immunization against P. aeruginosa in our sheep model was useful in decreasing lung vascular injury, it was of no value in preventing the bacterial injury to the alveolar epithelium as well as the formation of protein-rich, culturepositive pleural effusions. In contrast, when IgG antibody to P. aeruginosa was present in both the circulation and the airspaces in the vaccinated sheep instilled with immune serum (group 3), there was complete protection against all lung and pleural injury (Tables II, III , and IV, and Fig. 1 ) and a markedly enhanced killing of bacteria (Table V) . On the basis of complement depletion studies done in three sheep (data not shown), this effect did not depend on the presence of complement. In previous experiments, complement removal in neutropenic mice did not affect the protection offered by specific circulating IgG or IgA to P. aeruginosa (25) . Also, instillation of nonimmune serum with the bacteria in preliminary sheep studies was not associated with a reduction in injury or greater bacterial killing compared with instillation of P. aeruginosa in a 5% ovine albumin solution (data not shown). Therefore, these results strongly suggested that the primary protective factor in the group 3 sheep was the presence of IgG antibody to P. aeruginosa in the airspaces of the sheep lung. Therefore, the group 4 and group 5 studies using airspace instillation of IgG antibody to P. aeruginosa were designed to test this hypothesis.
Concurrent and prophylactic administration of IgG antibody to P. aeruginosa into the airspaces (groups 4 and 5) was not associated with any injury to the alveolar epithelial barrier nor the formation of culture-positive, exudative pleural effusions (Tables II, III , and IV). This protective effect was associated with increased killing of the bacteria in the airspaces (Table V) and no increase in the excess water in the lung and pleural space (Fig. 1) . The instillation of IgG antibody to P. aeruginosa in the airspaces concurrently with the bacteria instillation was still associated with a small accumulation of the vascular tracer, "1'I-albumin, in the extravascular space of the lung. However, the ratio of the '31I-albumin in the alveolar fluid compared with plasma was not different from the control experiments (Table III) . This result suggests that, although the concurrent administration of specific IgG with the bacteria optimally increased bacterial killing and prevented alveolar epithelial and pleural injury, a mild increase in lung endothelial permeability still occurred. Interestingly, pretreatment with IgG 24 h before the instillation of live P. aeruginosa (group 5) prevented the increase in lung endothelial permeability. This effect may have occurred because the 24-h pretreatment interval allowed time for some ofthe IgG instilled into the airspaces to cross the alveolar epithelial barrier and enter both the lung interstitium and the circulation, as we have reported occurs after instillation of various peptides into the airspaces of the normal lung (20, 26, 27) .
What is the significance of these results? First, the data clearly demonstrate that specific immunotherapy administered through the respiratory tract prevented the bacterial injury to the alveolar epithelium in healthy sheep. The pathogenic and prognostic significance of injury to the alveolar epithelial barrier has recently been examined in a prospective study of patients with acute lung injury (28) . In that clinical study, recovery of alveolar epithelial barrier function in patients with alveolar flooding and acute lung injury was associated with an excellent prognosis for resolution of lung injury and recovery from respiratory failure. Secondly, specific immunotherapy also prevented the dissemination of P. aeruginosa bacteria to the pleural space as well as the formation of protein-rich effusions. This protective effect was observed in nonimmune sheep instilled with IgG antibody with the bacteria or when the antibody was instilled 24 h before the bacterial instillation (groups 4 and 5). There was no protective effect in the vaccinated animals instilled with live P. aeruginosa bacteria in 5% ovine albumin solution (group 2). This result confirms that the presence ofcirculating antibody alone is not sufficient to prevent the local dissemination of P. aeruginosa to the pleural space. Since the instillation ofIgG antibody to P. aeruginosa into the alveoli was associated with an increase in the pulmonary clearance of P. aeruginosa bacteria (Table V) , the dissemination of these bacteria to the pleural space may not occur before the quantity of bacteria present into the airspaces of the lung has reached a critical level. In fact, preliminary experiments in our laboratory have shown that after I07 cfu of P. aeruginosa was instilled into rabbit lungs, the bacteria did not enter the pleural space (29) . In contrast, when 109 P. aeruginosa was instilled, the bacteria uniformly disseminated to the pleural space (29) . The development ofprotein-rich empyema after induction ofan experimental P. aeruginosa pneumonia is probably explained by injury to the epithelial barrier with subsequent movement of alveolar fluid, bacteria, and some interstitial fluid to the pleural space. We conclude that the prophylactic or concurrent instillation of IgG antibody to P. aeruginosa into the airspaces of the lung is beneficial for preventing injury to the alveolar epithelial barrier and the development of pleural infection associated with instillation of 10'0 P. aeruginosa organisms. Also, the intraalveolar administration ofthe IgG antibody to P. aeruginosa optimally increased lung bacterial killing. This study also demonstrated the inability of circulating IgG antibody P. aeruginosa to protect against lung epithelial and pleural injury probably because not enough IgG antibody enters the airspaces in the presence of moderate lung injury. These results may explain why P. aeruginosa can colonize patients so effectively; specific antibody may not enter the airspaces until the inoculum of P. aeruginosa has caused severe injury to the pulmonary epithelial barrier. Therefore, circulating IgG antibody is primarily available to aid in lung defense after more severe lung injury has occurred and larger amounts of circulatory plasma have entered the airspaces of the lung. The possible value of intraalveolar administration ofIgG antibody to P. aeruginosa for preventative or therapeutic purposes deserves further study.
